JAK3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Cerdulatinib, a reversible ATP-competitive inhibitor of JAK1, JAK2, and JAK3, demonstrated an overall response rate (ORR) of 35% in a Phase II clinical trial for PTCL [NCT01994382].